Results 101 to 110 of about 13,126 (223)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

Drug, Healthcare and Patient Safety, 2015
Michele Jara, Thomas Aquilina, Peter Aupperle, Adrian L Rabinowicz Acorda Therapeutics, Inc., Ardsley, NY, USA Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US ...
Jara M, Aquilina T, Aupperle P, Rabinowicz AL   +3 more
doaj  

Postmarketing evidence of disease-modifying drugs in multiple sclerosis

, 2008
There is growing interest in the use of observational data to estimate treatment effects in chronic diseases such as multiple sclerosis (MS). The main results derived from postmarketing evaluations, in the last 2 years, of short-and long-term disease ...
TROIANO, Maria, DIRENZO V, D'ONGHIA M., PAOLICELLI, DAMIANO, PELLEGRINI F, IAFFALDANO, PIETRO, FUIANI A   +6 more
core   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. [PDF]

BACKGROUND AND OBJECTIVE: Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, Crohns disease, and ulcerative colitis; however,
Chambers, Christina, Levy, Gweneth, Bhutani-Jacques, Tina, Lacerda, Ana, Kimball, Alexa, Gensler, Lianne, Wegrzyn, Lani, Long, Millie, Scialli, Anthony, Clowse, Megan, Mahadevan, Uma, Ali, Mira, Palac, Hannah   +12 more
core   +1 more source

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

BMC Gastroenterology
Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological
Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao   +7 more
doaj   +1 more source

RE: Systematic postmarketing surveillance needed for misused psychoactive pharmaceutical drugs-[3]

, 2013
RE: Systematic postmarketing surveillance needed for misused psychoactive pharmaceutical drugs ...
MDH Dobbin (15895574), AC Rintoul (15895571)   +1 more
core  

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events

Clinical and Translational Science, 2022
John T. Sullivan
doaj   +1 more source

FDA Censoring of Manufacturers\u27 Postmarketing Commitments in HIV/AIDS Drug Approval Letters

, 2000
Context: Changing evidentiary standards and partial shift of the investigational phase of drug approval process to the postmarketing phase. Objective: To determine the availability of information for independent researchers needed to examine accelerated ...
Shafer, Charles, Meinert, Curtis, Tonascia, Susan, Unalp-Arida, Aynur   +3 more
core  

Association of Guillain-Barré Syndrome With Nonavalent Human Papillomavirus Vaccine: A Postmarketing Drug Safety Study. [PDF]

Obstet Gynecol Int
González Mariño MA.
europepmc   +1 more source